Anthropic, the AI safety-focused company known for its Claude language models, has confirmed it operates a physical wet biology laboratory in the Bay Area where it uses its AI models to run physical experiments. The revelation marks a notable evolution for a company that has positioned itself as a leader in AI safety research, now moving beyond pure computation into hands-on biological manipulation.

The lab's existence came to light as Anthropic announced new pharmaceutical partnerships and a verification program for life sciences researchers, signaling a strategic push into biotechnology that has drawn both excitement and scrutiny from industry observers.

From Stealth Acquisition to Active Experimentation

Anthropic's wet lab capabilities stem from its April 2024 acquisition of Coefficient Bio, a stealth AI biotech startup. According to Eric Kauderer-Abrams, Anthropic's head of life sciences, the facility focuses on fundamental biology research rather than direct drug discovery efforts.

"We believe that to do biology, the final test is still, and will be for a while, in real lab work," Kauderer-Abrams told Reuters. "We absolutely are doing that today." He added that the lab operates like most biotech labs: Anthropic conducts some research there while also working with external partners.

This week, Anthropic launched its Life Sciences Verification Program, designed to provide vetted biology researchers with access to the company's most powerful AI models. The company has also published recent research on accelerating protein design and advancing biomolecular modeling.

Anthropic's biotech ambitions extend to high-profile partnerships, including a joint drug discovery collaboration with pharmaceutical giant Novo Nordisk. CEO Dario Amodei has made bold claims about the technology's potential, stating that "AI could cure most major diseases in the next 5–10 years."

Safety Warnings Meet Physical Biology

The juxtaposition of Anthropic's wet lab operations with its prominent AI safety messaging has not gone unnoticed. The company has been vocal about existential risks from artificial intelligence, with its alignment lead assessing a greater than 10% probability of AI-driven human extinction within a decade. Former researcher Jacob Coxon resigned from Anthropic warning that "the people building AI earnestly believe that it could kill us all by the end of the decade."

CEO Dario Amodei has published posts calling on the industry to slow down and institute self-regulation, repeatedly identifying bioterrorism as one of AI's biggest risks.

Investor and AI coding startup founder Chamath Palihapitiya publicly questioned this apparent contradiction, posting on X: "The group behind such hits as: 'We're All Going To Die' and 'Regulate Me Now' are building a wet lab in SF. I do not recommend this." The criticism points to broader questions about whether companies emphasizing AI catastrophic risk should simultaneously pursue hands-on biological experimentation.

Positioning as Infrastructure Provider

Despite operating its own lab, Anthropic appears to be positioning itself as an enabler rather than a competitor to pharmaceutical companies. The company declined to give specifics on what the wet lab is working on, but emphasized that the main focus was fundamental biology, not drug discovery.

Anthropic doesn't want to give the appearance of competing with the pharma industry, where it has numerous major customers and partners. The company has already faced backlash for launching products perceived to compete with those of its customers. By focusing on fundamental biology while partnering with pharma giants for drug discovery applications, the company may be seeking to avoid direct competition with established industry players.

The Life Sciences Verification Program further suggests Anthropic is working to establish controlled access to its biomedical AI applications. Whether this integrated approach—combining computational AI with physical experimentation—will accelerate the path from AI predictions to clinical applications remains to be seen, but Anthropic's move signals that leading AI companies increasingly view wet lab capabilities as essential to validating their models' real-world impact.

Sources

  1. Anthropic is operating a lab that conducts biology experiments — TechCrunch